Clinical Report: Oral Aleniglipron Reduced Weight at 36 Weeks

Overview

Aleniglipron, an oral GLP-1 receptor agonist, demonstrated significant weight loss in adults with obesity or overweight, achieving reductions of 9% to 12% at 36 weeks compared to 1% with placebo. The study also noted favorable changes in hemoglobin A1c and blood pressure, though gastrointestinal adverse events were common.

Background

The rising prevalence of obesity is associated with increased mortality and healthcare costs. GLP-1 receptor agonists have been approved for weight management and type 2 diabetes treatment.

Data Highlights

Key Findings

• Aleniglipron reduced body weight by 9% to 12% at 36 weeks in a phase 2b trial.
• 86% of patients on 120 mg achieved at least 5% weight loss compared to 23% on placebo.
• Hemoglobin A1c declined by 0.27 to 0.36 percentage points in aleniglipron groups.
• Gastrointestinal adverse events occurred in 79% to 89% of aleniglipron-treated patients.
• Serious adverse events were reported in 2% to 6% of patients across treatment groups.

Clinical Implications

Clinicians should consider aleniglipron as a potential treatment option for adults with obesity or overweight, particularly those with weight-related comorbidities. Monitoring for gastrointestinal adverse events is essential during treatment.

Conclusion

Aleniglipron reduced body weight by 9% to 12% at 36 weeks in a phase 2b trial, with gastrointestinal side effects reported.

Related Resources & Content

1. Nature Medicine, 2026 -- Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial
2. PubMed, 2026 -- Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
3. kff health news — GLP-1s: A Quiet Drop-Off in Seniors
4. The Journal of Clinical Endocrinology & Metabolism — Evaluating the Feasibility of a Low-Intensity Dietary Approach to Lower Triglycerides in Gestational Diabetes: A Randomized Controlled Trial
5. Nature Medicine — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
6. GLP-1s: A Quiet Drop-Off in Seniors
7. Evaluating the Feasibility of a Low-Intensity Dietary Approach to Lower Triglycerides in Gestational Diabetes: A Randomized Controlled Trial
8. Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity - PubMed
9. FOUNDAYO (orforglipron) tablets, for oral use — Highlights of Prescribing Information
10. Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial